Industry

DUBLIN–(BUSINESS WIRE)–The “Global Cardiac Monitoring Devices Growth Opportunities” report has been added to ResearchAndMarkets.com’s offering. This research service provides an overview of the global cardiac monitoring devices market. The geographical scope of this global study is North America (NA), Europe, and Asia-Pacific (APAC). It offers a detailed analysis of market sizing, trends, competitive landscape, future … [Read more…]

NASHVILLE, Tenn.–(BUSINESS WIRE)–HealthTrust Performance GroupSM, a leading improvement catalyst for healthcare, hosted the 24th annual HealthTrust University (HTU) conference to recognize, educate and inspire leading healthcare systems across the country around supply chain excellence, sustainability and innovation benefiting patients and communities. With the theme, “Boldly Forward, The Future of a World Disrupted,” the live event … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Sickle Cell Anemia Testing & Screening Market Research Report by Technology, Age Group, Sector, Region – Global Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering. The Global Sickle Cell Anemia Testing & Screening Market size was estimated at USD 805.21 million in 2021, USD 911.81 million … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “An Introduction to the Medical Device Regulation Training Course” conference has been added to ResearchAndMarkets.com’s offering. This seminar provides an invaluable overview of the European Medical Device Regulation (MDR). The interactive programme will explain the new legislation and which products are covered, the involvement of Notified Bodies and how to choose one and … [Read more…]

Q1 FY2022 Results Demonstrate a Strong Start to the Year with Core Revenue Growth at Constant Exchange Rate (CER) of +8.3% (Reported Revenue +2.4%) Growth and Launch Products Delivering Revenue Growth of +26% at CER Core Operating Profit Growth of +17% at CER, Core Operating Profit Margin 32.8% Reported Revenue and Operating Profit Growth Affected … [Read more…]

The last volunteer was enrolled in the REVERSE-IT study; recruitment of the 600 participants in this international, multicenter, randomized, placebo-controlled clinical study is complete. This Phase II/III study is evaluating the efficacy of TOTUM•63, a plant-based active substance, in a population with impaired glucose metabolism, from prediabetes to untreated type 2 diabetes (early stage). The … [Read more…]

– Overview of two decades of research to be presented, including development of gantenerumab – – Detailed results from Phase II study evaluating crenezumab in autosomal dominant Alzheimer’s disease – – Data around biomarker selection for the Elecsys Amyloid Plasma Panel, a blood-based biomarker test to aid in the detection of people with amyloid pathology, … [Read more…]

CHICAGO–(BUSINESS WIRE)–MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the pricing of its initial public offering of 2,000,000 shares of the Company’s common stock at a public offering price of $5.00 per share for aggregate gross proceeds of $10,000,000 prior to deducting underwriting … [Read more…]

AI-powered Viz SDH automatically detects subdural hemorrhage, enables effective triage and optimal care SAN FRANCISCO–(BUSINESS WIRE)–#AI–Insert after fourth paragraph of release: footnote 2. The updated release reads: VIZ.AI RECEIVES FDA 510(K) CLEARANCE FOR VIZ SDH AI-powered Viz SDH automatically detects subdural hemorrhage, enables effective triage and optimal care Viz.ai, the leading AI-powered disease detection and … [Read more…]

HAWTHORNE, N.Y.–(BUSINESS WIRE)–Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter ended June 30, 2022. Quarter ended June 30, 2022* Highlights ─ compared to June 30, 2021 Net sales increased $9.6 million, or 6.5%, to $156.7 million. Gross profit of $81.6 million (52.1% of net sales) … [Read more…]